Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

4.260 -1.580 (-27.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Via ACCESSWIRE
Earnings Scheduled For November 13, 2024
Via Benzinga
Jaguar Health Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Exploring Jaguar Health's Earnings Expectations
Via Benzinga
Lisa Conte, CEO of Jaguar Health Inc. (NASDAQ: JAGX), to Present at NobleCon20
Via Investor Brand Network
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Via ACCESSWIRE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Via ACCESSWIRE
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
Via ACCESSWIRE
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
Via ACCESSWIRE
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Via ACCESSWIRE
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Via ACCESSWIRE
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
Via ACCESSWIRE
Why Jaguar Health (JAGX) Stock Is Down 15%
Jaguar Health shares are trading lower by 15.4% during Tuesday's session. The company reported worse-than-expected second-quarter results. 
Via Benzinga
Jaguar Health Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Via ACCESSWIRE
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and
Via ACCESSWIRE
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Via ACCESSWIRE
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Via ACCESSWIRE
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
Via ACCESSWIRE
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Via ACCESSWIRE
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Via ACCESSWIRE
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Via ACCESSWIRE
JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024
JAGX stock results show that Jaguar Health missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Via ACCESSWIRE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.